Prostate Cancer Survival

prostate cancer survival

MONDAY, Feb. 23, 2015 (HealthDay News) -- Choosing active surveillance over treatment for prostate cancer may decrease the odds of survival in men with intermediate-risk cancer, a new study says. The risk of death over 15 years for men with intermediate One in six men will be diagnosed with prostate cancer in their lifetime. With early detection, survival is nearly 100 percent. Prostate On-Site Project, a medical mobile service, will be providing affordable prostate cancer screenings to men 40 years and (HealthDay News) -- Choosing active surveillance over treatment for prostate cancer may decrease the odds of survival in men with intermediate-risk cancer, a new study says. The risk of death over 15 years for men with intermediate-risk prostate cancers confirmed that radiation therapy is the number one treatment to address men suffering with prostate cancer despite the aggressiveness of the tumor, treatment risks and overall patient characteristics, background and prognosis. These findings were REUTERS: An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Key clinical point: Bicalutamide improved overall survival in men with locally advanced but not organ-confined prostate cancer. Major finding: After a median follow-up of 14.6 years, men with locally advanced disease who received 150 mg bicalutamide .

(HealthDay News) — Choosing active surveillance over treatment for prostate cancer may decrease the odds of survival in men with intermediate-risk cancer, according to research scheduled to be presented at the American Society of Clinical Oncology's Low nadir serum testosterone in the first year of androgen deprivation therapy was associated with improved survival and time to progression in men with recurrent prostate cancer, reported Dr. Laurence Klotz and his coauthors at the University of Toronto These predictions are based on the 2014 estimated number of new prostate cancer cases and the relative survival of patients with low- versus high-risk cancer. “Whether this effect can be attributed to the 2009 or 2011 recommendation by USPSTF is This is particularly pressing because this population constitutes the fastest growing subpopulation of cancer patients in the United States." Dr. Zheng and colleagues also found that blacks had poorer survival than whites for all cancers except prostate .